(Boston, MA) - "The language in the final FY20 House budget makes progress in bringing more transparency to prescription drug costs for the MassHealth program. MassHealth prescription drug costs have nearly doubled from $1.1 billion to $1.9 billion over the past five years, and MassHealth needs additional negotiating tools. While the transparency language in the House budget importantly includes additional reporting, as well as options for public input and hearings to inform additional rebates, there is more work to be done to make prescription drugs more affordable for consumers, employers and the state. There must also be increased accountability both within the MassHealth program and the private market to address unreasonably priced drugs. We look forward to continuing to work with the House and Senate this session to pursue transparency and accountability - only when we have both will all consumers start to feel some relief from the skyrocketing costs of prescription drugs."
Friday, April 26, 2019